The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials.

Cancers (Basel) · 2021 · PMC8657254 · PMID 34884981

Europe PMC DOI

hedged sentence

0.0850

closest p · 1.7× alpha

0.0850

boldest claim

The sentences

did not reach statistical significancep = 0.085so close (0.05 < p ≤ 0.1)

The benefit did not reach statistical significance ( p = 0.085) for patients with nmCRPC.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.